Syndax Pharmaceuticals (SNDX) Cash from Financing Activities (2015 - 2026)

Syndax Pharmaceuticals' Cash from Financing Activities history runs 12 years deep, the most recent figure standing at $7.9 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 751.4% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $20.7 million (down 94.13% YoY), while the FY2025 annual figure was $13.7 million, down 96.13% from the prior year.
• Cash from Financing Activities was $7.9 million for Q1 2026 at Syndax Pharmaceuticals, up from $5.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $347.4 million in Q4 2024 to a low of -$13.5 million in Q3 2022.
• Historically, Cash from Financing Activities has averaged $47.7 million across 5 years, with a median of $2.5 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities sank 893.26% in 2022, then jumped 751.4% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $163.5 million in 2022, then soared by 58.09% to $258.5 million in 2023, then jumped by 34.41% to $347.4 million in 2024, then sank by 98.3% to $5.9 million in 2025, then surged by 33.82% to $7.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $7.9 million (Q1 2026), $5.9 million (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.